Partner David Simon was quoted in a Bloomberg Quint article, “How U.S. Companies Are Navigating The FCPA Risk In India,” about the perils of doing business in India.
Under the Dodd Frank Act, Simon said, a whistle-blower who comes to the Securities Exchange Commission with actionable information that may result in an enforcement action under the Foreign Corrupt Practices Act is entitled to monetary awards. “I’m surprised by how well-known this fact is to Indian employees of U.S. companies,” he said.
Simon also said he doesn’t believe it’s impossible to do business in India without paying bribes. “It requires preparation, patience and resources, but it can be done,” he said.
Under the Dodd Frank Act, Simon said, a whistle-blower who comes to the Securities Exchange Commission with actionable information that may result in an enforcement action under the Foreign Corrupt Practices Act is entitled to monetary awards. “I’m surprised by how well-known this fact is to Indian employees of U.S. companies,” he said.
Simon also said he doesn’t believe it’s impossible to do business in India without paying bribes. “It requires preparation, patience and resources, but it can be done,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”